ADAURA Raises Questions About Optimal Use of Adjuvant EGFR TKIs in NSCLC
OncLive,
Over the past 2 decades, the field of EGFR -mutated non–small cell lung cancer (NSCLC) has grown tremendously, but the influx…
Over the past 2 decades, the field of EGFR -mutated non–small cell lung cancer (NSCLC) has grown tremendously, but the influx…
Why conduct post approval studies at all? Atezolizumab previously received accelerated approval in second-line metastatic or…
L'aggiunta dell’anticorpo monoclonale anti-VEGF bevacizumab alla chemioterapia adiuvante non ha migliorato i risultati di…
By Matthew Stenger Posted: 11/28/2017 9:45:27 AM Last Updated: 11/28/2017 9:45:27 AM Tweet this page Advertisement The addition…